MREOMereo BioPharma Group plc

Nasdaq mereobiopharma.com


$ 3.27 $ 0.11 (3.32 %)    

Tuesday, 28-May-2024 15:41:44 EDT
QQQ $ 454.82 $ -0.38 (-0.08 %)
DIA $ 398.57 $ -2.05 (-0.53 %)
SPY $ 530.36 $ -1.66 (-0.31 %)
TLT $ 91.26 $ -1.24 (-1.35 %)
GLD $ 225.37 $ 0.47 (0.22 %)
$ 2.95
$ 3.16
$ 3.25 x 100
$ 3.29 x 105
$ 3.10 - $ 3.50
$ 0.92 - $ 4.36
239,459
na
2.07B
$ 0.99
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-27-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-6-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.

 mereo-biopharma-group-q1-2024-adj-eps-001

Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which missed the analyst consensus estimate ...

 needham-reiterates-buy-on-mereo-biopharma-group-maintains-6-price-target

Needham analyst Gil Blum reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Buy and maintains $6 price target.

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 needham-maintains-buy-on-mereo-biopharma-group-raises-price-target-to-6

Needham analyst Gil Blum maintains Mereo BioPharma Group (NASDAQ:MREO) with a Buy and raises the price target from $5 to $6.

 mereo-biopharma-group-fy-eps-004-up-from-007-yoy-sales-1000m

Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.04) per share. This is a 42.86 percent increase over losse...

 cantor-fitzgerald-reiterates-overweight-on-mereo-biopharma-group-maintains-7-price-target

Cantor Fitzgerald analyst Kristen Kluska reiterates Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and maintains $7 p...

 why-intel-shares-are-trading-lower-by-over-10-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth q...

 booz-allen-hamilton-posts-upbeat-results-joins-appfolio-gentex-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded mixed, with the Dow Jones gaining around 80 points on Friday.

 mereo-biopharma-reiterates-previous-cash-runway-guidance-current-cash-expected-to-fund-operations-into-2026

Mereo BioPharma Group plc (NASDAQ:MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare ...

Core News & Articles

Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company ...

 why-is-mereo-biopharma-stock-trading-higher-today

Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase ...

 why-streamline-health-solutions-shares-are-trading-lower-by-over-68-here-are-other-stocks-moving-in-mondays-mid-day-session

Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION